46
Participants
Start Date
July 10, 2017
Primary Completion Date
October 11, 2021
Study Completion Date
March 1, 2027
Elotuzumab
Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
Carfilzomib
Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
Lenalidomide
Lenalidomide will be given on days 1-21 for all cycles.
Dexamethasone
"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"
University of Michigan Comprehensive Cancer Center, Ann Arbor
NorthShore University Health System, Evanston
University of Chicago, Chicago
Collaborators (2)
Bristol-Myers Squibb
INDUSTRY
Amgen
INDUSTRY
Multiple Myeloma Research Foundation
OTHER
University of Chicago
OTHER